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Abstract
Integrin α6β4 is a membrane protein which is expressed in both normal and cancerous epithelia . In normal cells, it is involved 
in adhesion to the basal membrane . In carcinomas, however, it takes on cell signaling roles related to survival and migration . Due 
to its key role in cancer progression, it is now being considered as a therapeutic target . This paper examines how we can affect 
integrins, with a specific focus on integrin α6β4, to reinforce their ability to prevent migration of cancer cells and progress toward 
metastasis .
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Methods
Data was collected using ProQuest, PubMed databases, 
and the National Library of Medicine. The images and di-
agrams can be found in the research articles referenced.
Introduction
Integrin α6β4 is a membrane protein found on the basal 
side of epithelial cells. It is a member of the integrin fam-
ily of proteins. Integrins are heterodimers which are im-
bedded in cell membranes and signal allosterically; ligand 
binding to extracellular binding sites causes conforma-
tional changes in the integrin which ultimately affect their 
cytoplasmic domains. These domains link to the cell’s 
cytoskeleton and thereby perform signal transduction. 
As much as their signaling works outward-inward, their 
signaling also works inward-outward. Integrins’ position 
in the cell makes them a key component in signaling, cell 
migration, and cell adhesions. Each integrin has a distinct, 
specific function, and, therefore, they have diverse ligands. 
Many integrins, including α6β4, can be turned on or off 
and need to be activated by tyrosine kinases or growth 
factors in order to bind to their ligands. 
Integrin α6β4 is different from other integrins because 
it has a unique β subunit, with an atypically long cytoplas-
mic domain which connects to the keratin intermediate 
filament system, as opposed to the microfilament system. 
The α subunit binds to its ligand, laminin 332, in the extra-
cellular matrix. Through mediating the interactions with 
laminin and keratin, integrin α6β4 is the core component 
of the hemidesmosome, a protein complex which attach-
es basal epithelial cells to the basement membrane.
Normally, integrin α6β4 is involved in hemidesmo-
somes and contributes to tissue stability. Cancerous cells, 
however, lack hemidesmosomes and integrin α6β4 is lo-
calized at the leading edges of metastasized carcinoma 
cells. Integrin α6β4 interacts with many cancer-related 
growth factors such as epidermal growth factor receptor 
(EGFR). Significantly, integrin α6β4 activates phospho-
inositide 3-OH kinase (PI3K), a key signaling molecule for 
carcinoma invasions. 
Because of integrins’ unique positioning in the cell and 
in cell signaling, they are highly involved in development 
of cancers. At times, integrins can inhibit pathways, and 
at times they can activate pathways instead. Therefore, 
integrins should be considered as a possible target for 
treating cancers. Integrin α6β4 can be considered as a 
model, as it attaches cells to the basement membrane and 
can contribute to invasion and metastasis of carcinomas. 
However, before examining cancerous cells, it is neces-
sary to understand the behavior of integrins in normal 
epithelial tissue.
Integrin α6β4 in Regular Cells
In healthy epithelial cells, integrin α6β4 occupies a central 
place in the hemidesmosome, a protein complex which 
connects epithelial cells to the basement membrane. 
There are two kinds of hemidesmosomes: type 1, which 
is found in stratified and pseudostratified epithelia (such 
as in the epidermis) and type 2, which is found in simple 
epithelia (such as in the intestine). In the more complex 
type 1 hemidesmosomes, integrin α6β4 facilitates the in-
teractions with most of the proteins involved, including 
the intracellular proteins plectin and BP180, the trans-
membrane proteins BP230 and tetraspanin CD151, and 
the extracellular protein laminin 332, which is part of the 
basal lamina (Walko et al, 2015). In the simpler type 2 
hemidesmosomes, the only components are plectin, lami-
nin, and integrin α6β4, which mediates the interactions 
between the other two. Integrin α6β4’s presence even in 
these simplified hemidesmosome proves that it is essen-
tial for the adhesion of epithelial cells to the basement 
membrane below (de Pereda et al, 2009). Additionally, 
mice missing β4 exhibited pathology similar to junctional 
epidermolysis bullosa, a human disease characterized by 
fragile skin that blisters quickly due to the basal layer’s 
separation from the basement membrane. The epitheli-
al tissues of the mice, both simple and stratified, lacked 
hemidesmosomes and did not adhere normally (Dowling 
et al, 1996).
The α6 subunit is homologous to other integrin α sub-
units. α6, like many other integrin protomers, associates 
with more than one β subunit. For instance, α6β1 is an 
integrin found in the retina and cortex, and is linked to 
disorders of those tissues (Hynes, 2002). When it is found 
in epithelial cells, however, it is exclusively associated with 
β4 and binds to laminin as its ligand. α6 is made up of 
46
Pearl Singer
1,055 amino acids, with the first 1,011 outside the cell, 
36 in the transmembrane region, and 19 in the cytoplasm. 
(Tamura et al, 1990). The amino domain has 7 homolo-
gous repeats, which were found to make up a 7-bladed 
β propeller (Kamata et al, 2001). It is made up of two 
polypeptides, a heavy chain and a light chain, which origi-
nated from one polypeptide but which were cleaved using 
post-translational modification.  They are joined by a di-
sulfide bridge, similar to α5, αv, α11b, and αP52. However, 
it does not contain the insert domain near the amino ter-
minus that other α subunits possess (Tamura et al, 1990). 
β4 has 710 amino acids in its extracellular region, with 
cysteine conservation of that region the same as that of 
other β subunits. It has a 23 amino acids in its transmem-
brane region and has 1089 amino acids in its cytoplasmic 
region (Tamura et al, 1990). The cytoplasmic domain is 
made up of 5 globular domains. From the membrane to-
ward the inside of the cell, they are: a Na+- Ca+ Calx-β 
exchange motif, a pair of fibronectin type III domains 
(FnIII-1,2), and another pair of fibronectin domains (FnIII-
3,4). Between the two pairs of FnIII domains, there is a 
flexible connecting segment (CS), and after the second 
set, there is a c-terminal tail (Walko et al, 2015). There 
are 5 possible N-glycosylation sites, all of which are gly-
cosylated (Tamura et al, 1990).
Over time, a clearer picture of α6β4 has been formed. 
Scanning electron microscopy revealed that both sub-
units have a large globular head and a stalk portion which 
then traverses the cell membrane. The two protomers 
complex by binding their heads together (Luo, 2007). α6’s 
amino domain contains a 7-bladed β propeller domain, 
which is made up of 7 four-strand β sheets similar to 
those found in other integrins, which is topped by a ligand 
binding site. However, it lacks the “insert” domain, other-
wise known as a Von Willebrand Factor A domain, which 
has a MIDAS (a cation coordination site), that is found 
imbedded in the propeller of the majority of integrins 
(Kamata et al, 2001). This makes sense because only integ-
rins that are exclusive to chordates have this domain, and 
α6β4 is homologous to that of more primitive species. 
When an integrin has this insert domain, cation coordina-
tion to the MIDAS site causes a conformational change in 
the protein, pulling part of the α6 head further down and 
allowing the ligand to bind to its binding site. 
Ligand binding occurs differently in integrins lacking this 
insert domain like α6β4. In this integrin, β4 has its own 
insert domain with a MIDAS motif, which, when inactive, 
is in contact with α6’s propeller. When the C-terminus 
of β4 moves downward, or when a cation binds to the 
MIDAS, it pulls the rest of the protein, exposing more of 
the propeller surface to allow for a greater affinity for 
ligand binding (Hynes, 2002). When priming and ligand 
binding occur, a large-scale conformational change over-
comes both subunits. In their resting, low-affinity phase, 
both subunits’ stalks are bent downward in the middle 
in a genuflected position, with their intracellular domains 
touching. When ligand binds, the subunits straighten in a 
switchblade-like motion and the legs separate, exposing 
binding surfaces. This is one instance of allosteric signaling 
in integrins (Luo, 2007).
The majority of connections in the hemidesmosome 
occur with the large intracellular domain of β4. The four 
FnIII domains have a conserved hydrophobic core, with 
9 out of 11 identical residues, but their outer surfaces, 
which are exposed to solvent, are entirely different, so 
they can bind to different groups (Alonso-Garcia et al, 
2015). The critical interaction within the hemidesmo-
some is between β4 and plectin. Plectin binds to the IFs 
in the cell, while α6’s interaction with β4 allows it bind 
to its ligand, laminin. The two proteins join at β4’s second 
Fn-III domain and at plectin’s actin-binding domain (ABD). 
This complex is formed by three sets of ionic interac-
tions: between R1225 of β4 and D151 of plectin, between 
R1281 of β4 and E95 of plectin, and between E1242 of 
β4 and R98 of plectin. Missense mutations in one of the 
residues involved in these salt bridges disturbs the inter-
action with plectin. The first 7 residues of the connecting 
segment also play a part in this interaction by extending 
the binding surface of the Fn-III domain. The first FnIII 
domain also contributes to the interaction through a hy-
drophobic pocket made up of I1163, Y1187 and C1190, 
which interacts with an R-side chain in plectin. When β4 
binds to plectin, a conformational change is triggered in 
β4; in unbound β4, part of the CS is folded over FnIII-2 
and engages in antiparallel H-bonding with it. In bound β4, 
that part of the CS is unbent and may reveal binding sites 
for other proteins in the hemidesmosome, like BP230 
and BP180 (de Pereda et al, 2009). 
Integrin α6β4 in Wounded Cells
Although integrin α6β4 is associated with cell adhesion, 
it is also involved in signaling pathways associated with 
cell migration, differentiation, and proliferation. These 
processes assist in healing wounds. This is indicated by 
its localization to the front edge of cells migrating into a 
wound.  Additional proof can be seen in an experiment 
involving A549 (adenocarcinomic human alveolar basal 
epithelial) cells. When the β4 gene was knocked down, 
the cells migrated less processively than the controls. 
When the α6 gene was knocked down, the cells migrated 
both less processively and more slowly. Examination of 
keratinocytes has revealed that wild-type keratinocytes 
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move on a straight line along their matrix of laminin, while 
β4-deficient keratinocytes move in a circular fashion. All 
of this shows that integrin α6β4 plays an essential role in 
healing wounds (Colburn, Jones, 2017).
In order for cells to migrate toward a wound bed, the 
hemidesmosomes need to disassemble, a process that 
begins from the cytoplasmic domain and then contin-
ues in the extracellular domain. β4 serine residues are 
first phosphorylated by tyrosine kinases to separate β4 
from its binding partner, plectin; this is stimulated by 
epidermal growth factor (EGF) (Mainero et al, 1996), as 
well as protein kinase C (Rabinovitz, et. al. 1999). After 
β4’s phosphorylation, the rest of the connections in the 
hemidesmosome are then severed (Walko et al, 2015). At 
this point, α6β4 detaches from the intermediate filament 
(keratin) cytoskeleton and instead associates with the 
actin cytoskeleton. It becomes involved in the formation 
of lamellae and filopodia, which are protrusions of the cell 
membrane that give the cell motility.
Epithelial cells involved in wound healing are similar to 
metastasizing carcinoma cells, allowing comparisons to be 
drawn between them. In both cases, there is a lack of 
polarization in the cells and an induction of migration. 
(Rabinovitz et al, 2015). Importantly, many of the same 
mechanisms are involved, including the coordination with 
growth factors, the disassociation from the hemidesmo-
some, and the formation of lamellae and filopodia.
Integrin α6β4 in Carcinoma
In many types of carcinomas, high levels of integrin α6β4 
correlate with the invasiveness of the cancer, as well as 
the patient prognosis. For example, in basal-type breast 
cancer, which is a highly aggressive form of breast can-
cer, a β4 “gene signature” was associated with decreased 
time to tumor recurrance and a smaller chance of pa-
tient survival (Lu, 2008). Other research shows similar 
correlation with elevated β4 expression in other invasive 
phenotypes of squamous cell carcinomas, including some 
kinds of bladder (Grossman et al, 2000), cervical (Jeffers 
et al, 1997), head and neck (Kurokawa et al, 2008), lung 
(Stewart et al, 2016), and pancreatic (Cruz-Montseratte 
et al, 2007) carcinomas. Interestingly, although thyroid 
cells do not normally express α6β4, it has been found 
in thyroid carcinomas (Kitajiri et al, 2002). In addition to 
overexpression of α6β4, it is also located throughout 
multiple layers of cells in tumors, as opposed to its nor-
mal concentration of the basal side of the epithelial cells 
(van Waes et al, 1995).
However, in some varieties of cancer, integrin α6β4 
expression is correlated with tumor suppression. For 
example, in prostate carcinomas, α6β4 is downregulated 
(Nagle et al, 1995). Also, when α6β4 was added to cells 
from the RKO cell line, a colon carcinoma cell line which 
is missing β4, the result was partial G1 arrest and apopto-
sis (Clarke et al, 1995). Because this integrin is associated 
with both growth and migration, but with suppression as 
well, it may be hard to target as a treatment for cancer. In 
order to examine treatment options, an in-depth look at 
the mechanism of action of integrin-implicated signalling 
pathways must take place.
Integrin α6β4 Signalling Mechanism
When integrin α6β4 is released from hemidesmosomes, 
it leads to altered signals promoting tumor cell growth, 
invasion and metastasis (Lipscomb, Mercurio, 2005). Once 
free from the hemidesmosome interaction, integrin α6β4 
can bind or cooperate with many different molecules or 
growth factor receptors to activate various cell signal-
ling pathways. Integrin α6β4 can bind directly to its reg-
ular ligand, laminin, activating both phosphatidylinositol 
3-kinases (PI3K) and RhoA small GTPases. Alternatively, 
it can cooperate with various growth factor receptors, 
including those in the EGFR (epidermal growth factor 
receptor) family, such as ErbB-1,2, and 3 (Guo et al, 
2006), as well as c-Met (Chung et al, 2004), Ron, LPA1 
and LPA2 (O’Connor et al, 2012). This leads to intensifi-
cation of signaling through PI3K, AKT, MAPK and the Rho 
small GTPases, as depicted in Figure 1. Integrin α6β4 can 
also promote tumor progression through transcriptional 
regulation. It has been shown to increase the expression 
of invasive and metastatic proteins such as the epithe-
lial to mesenchymal transition (EMT)-associated protein 
S100A4 (Stewart, O’Connor, 2015).
Figure 1 (Stewart, O’Connor, 2015)
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Integrin α6β4 is involved in the PI3K pathway, a signal-
ing pathway known for promoting carcinoma progression 
(Shaw et al, 1997). However, the cytoplasmic domain of 
the integrin β4 subunit does not have a consensus-bind-
ing motif for the regulatory subunit of PI3K , so direct ac-
tivation of the pathway does not seem possible. One pos-
sible mechanism for integrin β4-mediated activation of 
PI3K involves insulin receptor substrate-1 and −2 (IRS-1 
and IRS-2), which act as signaling intermediates facilitating 
integrin α6β4-mediated PI3K activation. Ligation of inte-
grin α6β4 promotes phosphorylation of IRS-1 and IRS-2, 
and then activation of PI3K (Shaw, 2001). Additionally, in-
tegrin α6β4 cooperates with ErbB-2 to promote PI3K-
dependent invasion (Gambaletta et al, 2000). Integrin 
α6β4 has also been shown to localize to lipid rafts in the 
membrane, allowing it to recruit other receptor tyrosine 
kinases, and thus allowing it to activate PI3K (Gagnoux-
Palacios et al, 2003).
ErbB-2 is one of the members of the EFGR family which 
signals for invasion and aggression in breast carcinoma. 
Integrin α6β4 has been shown to associate with ErbB-2 in 
multiple breast carcinoma cell lines (Falcioni et al, 1997). 
Although ErbB-2 is implicated upstream of PI3K, ErbB-2 
does not have a binding site for the regulatory subunit of 
PI3K. ErbB-2, as a receptor tyrosine kinase, must dimerize 
with another receptor to function. In this case, it dimeriz-
es with an ErbB-3, a different EGFR receptor. Erb-B3 has 
a binding site for PI3K’s regulatory subunit, and this het-
erodimer is a strong activator of PI3K. There is a positive 
association between integrin α6β4 and ErbB-3 expres-
sion in patient-derived tumors (Folgiero et al, 2008).
Other receptor tyrosine kinases that cooperate with 
integrin α6β4 include c-Met, which is activated by HGF 
(hepatocyte growth factor); a complex of α6β4 and 
c-Met was shown to promote HGF dependent invasion 
(Trusolino et al, 2001). Ron, a tyrosine kinase receptor 
closely related to c-Met, has been shown to form a com-
plex with integrin α6β4 that induces hemidesmosome 
disassembly and the relocation of integrin α6β4 to mo-
tility structures. Ron activation is important in pancreatic 
carcinoma progression, and it interacts with the integrin 
β4 subunit in this setting to disrupt the association be-
tween integrin β4 and plectin (Yu et al, 2012).
Integrin α6β4 also upregulates the Rho family of small 
GTPases. The Rho family of small GTPases control the 
reorganization of the actin cytoskeleton required for cell 
motility (Machacek, et. al. 2009). The activation of RhoA 
leads to lamellae formation, as well as the generation of 
contraction forces that enable cell migration (O’Connor 
et al, 2000). Significantly, RhoA generally controls the gen-
eration of stress fibers rather than lamellae formation, 
suggesting that integrin α6β4 changes RhoA’s function to 
facilitate tumor invasion (Stewart, O’Connor, 2015).
Integrin α6β4 can also stimulate angiogenesis by en-
hancing signaling through the protein kinase ERK and 
transcription factor NF-κB. Studies using knockout mice 
carrying a deletion in the signaling domain of the integ-
rin β4 subunit displayed reduced angiogenesis in a retinal 
neovascularization model, and developed smaller and less 
vascularized tumors after subcutaneous implantation. The 
same study demonstrated that the integrin β4 subunit 
could promote both bFGF (basic fibroblast growth fac-
tor)- and VEGF (vascular endothelial growth factor)-in-
duced angiogenesis by enhancing signaling through ERK 
and NF-κB (Nikolopoulos et al, 2004).
Cell Survival and Tumor Suppression
Returning to the paradox above, integrin α6β4 promotes 
either cell survival or apoptosis, depending on context. 
For instance, in normal epithelial cells, integrins promote 
survival when in contact with the extracellular matrix. 
However, once separated, the loss of integrin signaling can 
inhibit cell growth and promote anoikis, a form of apop-
tosis (Ruoslahti, Reed, 1994). Similarly, in cancer, at times 
integrin α6β4 acts as a promoter of cell survival, while at 
times it acts as a tumor suppressant.
To discover why these two different scenarios exist, 
a group studied two cell lines. In the RKO cell line, β4 
led to increased apoptosis, while in the MDA-MB-435 
cell line, β4 did not induce apoptosis. They discovered 
that the difference lay in the cells’ p53, a protein which is 
often implicated in cancer when mutated. RKO cells have 
wild-type p53, while MDA-MB-435 cells have mutant p53 
(Bachelder et al, 1999). Integrin α6β4 can trigger apop-
tosis through p53 activation in cells harboring wild-type 
p53; however, in carcinoma cells deficient in p53, integrin 
α6β4 promotes cell survival by activating the PI3K path-
way and through growth factors such as VEGF (vascular 
endothelial growth factor). This discovery suggests that 
tumors expressing high levels of integrin α6β4 in con-
junction with mutated p53 are resistant to apoptosis and 
will therefore display a more aggressive clinical course. 
Interestingly, an association between p53 mutations and 
integrin α6β4 overexpression is present in a number of 
aggressive human malignancies, including basal-like breast 
cancer, head and neck squamous cell carcinoma, and 
pancreatic ductal adenocarcinoma (Stewart, O’Connor, 
2015).
Treating Carcinomas Through Integrin 
Modification
Since integrins were discovered as molecules involved in 
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cancer, there has been a move to target them in cancer 
treatment. However, drugs developed to impact integrins 
have largely been unsuccessful. It’s possible that it is be-
cause the integrin-targeting drugs may only have moder-
ate affinity in vivo for integrin receptors, as shown by the 
doses used in clinical trials. Another reason may be that 
integrin antagonists work best when inhibiting early met-
astatic spread and not in advanced cancer stages, when 
cancer cells are already widespread (Paolillo, Schinelli, 
2017)
Another issue may be that the wrong integrins have 
been targeted. Not all integrins have been thoroughly 
explored as therapeutic targets, including integrin α6β4. 
That said, a common issue for all the integrins is that 
cells express multiple integrins at the same time, and if 
one would be targeted in treatment, the others might 
compensate for it. That explains why the drugs given were 
well tolerated with few ill effects, but also did not im-
pact the cancer. The solution would be to try and impact 
multiple integrins at once, but that might be difficult to 
achieve in a patient (Alday-Parejo et al, 2019).
The issue may also not be the stage or affinity, but the 
drug target itself. Most drugs designed for integrins target 
the integrin-ligand interaction; in this case, they would 
try to competitively inhibit the interaction between the 
integrin’s extracellular side and laminin 332. This could be 
a problem because integrins signal allosterically, so if an 
inhibitor would bind to the integrin’s ligand binding pock-
et, it could actually turn on the integrin and the signalling 
cascades could begin. The cytoplasmic domain may be a 
better option (Alday-Parejo et al, 2019).
Thus far, one group has worked on an inhibitor tar-
geting the cytoplasmic side of integrin α6β4. They found 
that curcumin, a yellow pigment derived from turmeric, 
inhibited the interaction between the cytoplasmic tail and 
EGFR, which is implicated in the PI3K pathway related 
to survival, invasion, and metastasis. EGFR is activated 
when the residues Y1068 and Y1045 are phosphorylated; 
when α6β4 was knocked out, there was significantly less 
phosphorylation, showing a connection between the two 
structures. They added curcumin to other cells and found 
that it had a similar effect on EGFR phosphorylation as 
knocking down α6β4. The hemidesmosomes in cells with 
curcumin remained stable upon stimulation with EGF 
(Soung, Chung, 2011).
Discussion/Conclusion
Integrin α6β4 plays an essential part in both regular and 
cancerous cells. Significantly, it contributes to the PI3K 
pathway, related to cancer aggression and survival. Integrin 
α6β4 should definitely be studied, both as a diagnostic 
tool and as a target for therapeutic intervention. As dis-
cussed above, it is a predictor of the cancer’s severity and 
can be used in a diagnostic setting. More research should 
be put into targeting its intracellular interaction with 
growth factors so that these pathways can be inhibited.
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